News

Post-transplant follow-up is crucial for hematopoietic stem cell transplant (HSCT) patients. Regular check-ups help detect issues like infections, graft-versus-host disease (GVHD), and relapse, ensuring early intervention and better outcomes.

A new study shows that CAR-T therapy can improve the prognosis for patients with high-grade B-Cell Lymphoma (HGBL), a subtype of large B-cell lymphoma, even in later treatment lines, offering new hope for these challenging cases.

A retrospective study comparing early versus late CAR-T therapy in large B-cell lymphoma patients reveals that earlier treatment may offer improved survival rates and fewer side effects, supporting its use as a second-line treatment.

A recent study published in The Lancet Rheumatologydemonstrates that CAR-T cell therapy is both safe and effective for treating lymphoma and Multiple Myeloma patients who also have autoimmune or inflammatory diseases, providing promising evidence for its broader application.

A comprehensive review in Bloodhighlights recent advancements in the understanding of genetic subtypes of adult B-cell Acute Lymphoblastic Leukemia (B-ALL). The study explores biological heterogeneity, clinical implications, and the significance of Precision Medicine in improving patient outcomes.

A phase 1 multicenter trial in China has demonstrated promising safety and efficacy of prizlon-cel, a dual-targeted CD19/CD20 CAR-T therapy, offering renewed hope for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).

A recent study published in Blood identifies soluble BCMA (sBCMA) levels and metabolic tumor volume (MTV) as potential biomarkers for predicting CAR-T therapy outcomes in relapsed and refractory multiple myeloma (RRMM) patients, paving the way for personalized treatment strategies.

CAR-T therapy, originally a breakthrough for B-cell malignancies, is showing promise in treating T-cell lymphomas and T-cell acute lymphoblastic leukemia (T-ALL). This evolving treatment faces unique challenges but recent clinical trials offer hope for new therapeutic solutions in T-cell malignancies.

The Lu Daopei Medical Team achieves a groundbreaking advancement in treating Acute Myeloid Leukemia (AML) with their study on nanobody-based CD7 CAR-T therapy, published in the prestigious journal Blood.

Recent advancements in Menin inhibitors offer promising treatment options for acute myeloid leukemia (AML), targeting genetic mutations and providing new hope for challenging cases.

At the 2024 ASH Annual Meeting, Professor Sun Yuqian shared his groundbreaking research on breakthrough invasive fungal disease (bIFD) in patients with hematologic malignancies, highlighting diagnostic and therapeutic challenges, as well as practical insights based on recent studies.

A new study published in Blood refines the risk stratification for T-cell acute lymphoblastic leukemia (T-ALL) using next-generation sequencing (NGS), enhancing prognosis predictions and identifying high-risk subgroups that could benefit from targeted therapies.